Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00732641
First received: August 8, 2008
Last updated: June 2, 2014
Last verified: June 2014
  Purpose

This study aims to assess the efficacy of peginterferon α-2b, compared to a control arm not receiving any maintenance treatment, in adult subjects with multiple myeloma who have responded to a prior induction therapy. Peginterferon α-2b will be given once weekly as an injection until disease progression or relapse, or for up to a maximum of 5 years (whichever occurs first).


Condition Intervention Phase
Multiple Myeloma
Drug: Peginterferon
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III Randomized, Prospective Multi-center Trial of PEG-Interferon α-2b as a Maintenance Therapy, Compared to Observation, in Patients With Multiple Myeloma Who Responded to Induction Therapy (Protocol No P01972)

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Number of Days With Progression Free Survival (PFS) [ Time Frame: Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse) ] [ Designated as safety issue: No ]

    PFS was defined as response duration while on maintenance therapy. It was the length of time during and after treatment in which a participant was living with the cancer that did not get worse.

    PFS was calculated from the date of randomization to the date of the first documented tumor progression or relapse.



Secondary Outcome Measures:
  • Number of Days of Overall Survival (OS) [ Time Frame: Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse) ] [ Designated as safety issue: No ]

    OS was calculated from the date of randomization to the date of death for any

    cause. Participants alive at the end of study were censored at the last date they were known to be alive. Participants who were still living at the end of the study were censored on the last date they were known to be alive.


  • Number of Participants With Complete Response (CR) to Treatment [ Time Frame: Month 9 & Month 18 ] [ Designated as safety issue: No ]

    CR was defined as:

    • Absence of the original monoclonal paraprotein in serum and urine by immunofixation, maintained for a minimum of 6 weeks;
    • <5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy, if biopsy was performed.
    • No increase in size or number of lytic bone lesions (development of a compression fracture did not include response);
    • Disappearance of soft tissue plasmocytomas.

  • Number of Participants With Partial Response (PR) to Treatment [ Time Frame: Month 9 & Month 18 ] [ Designated as safety issue: No ]

    PR was defined as:

    • At least 50% reduction in the level of the serum monoclonal paraprotein, maintained for a minimum of 6 weeks;
    • Reduction in 24-hour urinary light chain excretion either by ≥ 90% or to < 200 mg, maintained for a minimum of 6 weeks;
    • For patients with non-secretory myeloma only, ≥ 50% reduction in plasma cells in a bone marrow aspirate and on a trephine biopsy, if biopsy was performed, maintained for a minimum of 6 weeks;
    • At least 50% reduction in the size of soft tissue plasmacytomas;
    • No increase in size or number of lytic bone lesions.

  • Number of Participants With Minimal Response (MR) to Treatment [ Time Frame: Month 9 & Month 18 ] [ Designated as safety issue: No ]

    MR was defined as:

    • A 25-49% reduction in the level of the serum monoclonal paraprotein maintained for a minimum of 6 weeks;
    • Reduction in the 24-hour urinary light chain excretion, which still exceeded 200mg/24 hours, maintained for a minimum of 6 weeks;
    • For patients with non-secretory myeloma only, 25-49% reduction in plasma cells in a bone marrow aspirate and on a trephine biopsy, if biopsy was performed, maintained for a minimum of 6 weeks;
    • A 25-49% reduction in the size of soft tissue plasmacytomas;
    • No increase in the size or number of lityc lesions.

  • Number of Participants With Progressive Disease(PD) or Relapse From CR [ Time Frame: Month 9 & Month 18 ] [ Designated as safety issue: No ]

    PD (for patients not in CR) required one or more of the following:

    • 25% increase in serum monoclonal paraprotein level, 24-hour urinary light chain excretion, or plasma cells;
    • Increase in size of existing or development of new bone lesions/soft tissue plasmacytomas;
    • Development of hypercalcemia.

    Relapse from CR required at least one of the following:

    • Reappearance of serum or urinary paraprotein;
    • >5% plasma cells;
    • Development of new lytic bone lesions or soft tissue plasmacytomas or increase in the size of residual bone lesions;
    • Development of hypercalcemia.

  • Quality of Life [ Time Frame: Screening and Last Observation (up to 5 years) ] [ Designated as safety issue: No ]
    Participants were given the Europen Organization for Research in Cancer Therapy Quality of Life Questionnaire (EORTC QLQ), version 2.0, which consisted of 30 questions. The questionnaire evaluated global health/quality of life and incorporated five functional scales (Physical; Role; Emotional; Cognitive; Social). All of the scales ranged in score from 0 (worst) to 100 (best).


Enrollment: 244
Study Start Date: December 2000
Study Completion Date: November 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Peginterferon α-2b
Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
Drug: Peginterferon
Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
No Intervention: No Treatment
Participants will be observed and will receive no treatment.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must demonstrate willingness to participate in the study and to adhere to dose and visit schedules
  • Must be ≤85 years of age of either sex, and any race
  • Must have stage II or III multiple myeloma with a histological confirmation consistent with the

diagnosis of multiple myeloma (by biopsy of an osteolytic or soft tissue tumour composed of plasma cells or bone marrow aspirate and/or biopsy demonstrating ≥ 10% plasmacytosis). The histological

confirmation should have been obtained prior to the induction chemotherapy or bone marrow transplant chemotherapy

  • May not have received prior interferon for the treatment of multiple myeloma
  • Must confirm that he/she is practicing adequate contraception
  • If a female volunteer of childbearing potential, must have a negative serum pregnancy test

at Screening/Visit 1

-Must be free of any clinically relevant disease (other than multiple myeloma) that would, in the

principal investigator's and/or sponsor's opinion, interfere with the conduct of the study or study

evaluations

  • Must be able to adhere to the dosing and visit schedules
  • Clinical laboratory tests (complete blood chemistry [CBC], blood chemistries, urinalysis) must be

consistent with adequate hepatic and renal function, defined as <2 times upper limit of any laboratory normal (ULN) and adequate hematological functions defined as platelets > 50,000/mm^3, Hemoglobin ≥9.0 g/dL, white blood count (WBC) count ≥2000/mm^3

-Must have a complete, partial or minimal response after either one induction chemotherapy

regimen or one myelosuppressive chemotherapeutic treatment followed by peripheral blood stem cell

infusion as a first line treatment. Any type of pre-transplant chemotherapy and conditioning regimen is allowed

-Performance Status Karnofsky score of ≥60% at time of randomization

Exclusion Criteria:

  • Is a female who is pregnant, or intends to become pregnant during the study
  • Is nursing, or intends to be nursing during the study
  • Has used any investigational product within 30 days prior to enrollment
  • Have any of the following clinical conditions:

    • Pre existing psychiatric condition, especially depression, or a history of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or suicidal attempt. Subjects with a history of mild depression may be considered for entry into the protocol provided that a pre-treatment assessment of the subject's mental status indicates that the subject is clinically stable and that there is ongoing evaluation of the patient's mental status during the study
    • Central Nervous System (CNS) trauma or active seizure disorders requiring medication
    • Significant cardiovascular dysfunction within the previous 6 months before the study starts (eg, angina, congestive heart failure, recent myocardial infarction, severe hypertension or significant arrhythmia) or patient with multigated acquisition (MUGA) or echocardiogram < 40%;
    • History of prior malignant disease within the previous 5 years before the study starts, except for surgically cured squamous cell or basal cell skin carcinoma or Stage I cervical carcinoma or cervical carcinoma in situ;
    • Known severe coagulation disorders, thrombophlebitis or pulmonary embolism or decompensate liver disease;
    • Uncontrolled diabetes mellitus or thyroid dysfunction (not responsive to therapy);
    • Severe chronic pulmonary disease (eg, chronic obstructive pulmonary disease);
    • Has active and/or uncontrolled infection
  • Is in a situation or condition that, in the opinion of the investigator, may interfere with optimal

participation in the study

  • Is participating in any other clinical study
  • Is on the staff, affiliated with, or a family member of the staff personnel directly involved with this study
  • Is allergic to or has sensitivity to the study drug or its excipients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00732641     History of Changes
Other Study ID Numbers: P01972
Study First Received: August 8, 2008
Results First Received: October 27, 2011
Last Updated: June 2, 2014
Health Authority: Italy: Ministry of Health

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on October 01, 2014